Carcinoembryonic antigen-related cell adhesion molecule (CD66) (CD66)

CD66, also known as the Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM) family, consists of several highly glycosylated proteins (CD66a-e) belonging to the immunoglobulin superfamily (Source: UniProt). These molecules are predominantly expressed on the surface of myeloid cells, including granulocytes and their precursors, as well as various epithelial cells (Source: PubMed, PMID: 15141351). In hematologic malignancies, CD66 members—particularly CD66c (CEACAM6)—are frequently overexpressed on leukemic blasts in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (Source: Blood Journal). This expression pattern makes CD66 an attractive target for radioimmunotherapy (RIT), where monoclonal antibodies like besilesomab, labeled with radionuclides such as Yttrium-90, deliver targeted radiation to the bone marrow (Source: Journal of Nuclear Medicine). Such treatments are primarily employed as part of conditioning regimens prior to hematopoietic stem cell transplantation to eradicate residual leukemic cells while minimizing systemic toxicity (Source: StatPearls). Beyond oncology, CD66 is utilized in diagnostic imaging (immunoscintigraphy) to localize sites of infection and inflammation due to its high expression on activated neutrophils (Source: European Medicines Agency).

Other names

CEACAMBiliary glycoproteinBGPNonspecific cross-reacting antigenNCACarcinoembryonic antigen gene family memberCGMCD66aCD66bCD66cCD66dCD66e

Targeted delivery of radionuclides to myeloid cells and leukemic blasts for radioimmunotherapy (to induce cell death via ionizing radiation) or diagnostic immunoscintigraphy (to visualize infection or inflammation).